Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.

被引：0
|
作者：
Burotto, Mauricio
Powles, Thomas
Escudier, Bernard
Apolo, Andrea B.
Bourlon, Maria Teresa
Shah, Amishi Yogesh
Suarez, Cristina
Porta, Camillo
Barrios, Carlos H.
Richardet, Martin
Gurney, Howard
Kessler, Elizabeth R.
Tomita, Yoshihiko
Bedke, Jens
George, Saby
Scheffold, Christian
Wang, Peter
Fedorov, Viktor
Motzer, Robert J.
Choueiri, Toni K.
机构：
[1] Bradford Hill Clin Res Ctr, Santiago, Chile
[2] Barts Canc Ctr, London, England
[3] Royal Free London NHS Fdn Trust, London, England
[4] Gustave Roussy, Villejuif, France
[5] NCI, Ctr Canc Res, NIH, Bethesda, MD USA
[6] Inst Nacl Ciencias Med Nutr, Mexico City, Mexico
[7] MD Anderson Canc Ctr, Houston, TX USA
[8] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[9] Univ Pavia, Pavia, Italy
[10] Ctr Pesquisa Oncol, Porto Alegre, Brazil
[11] Inst Oncol Cordoba, dn Richardet Longo, Cordoba, Argentina
[12] Westmead Hosp, Sydney, NSW, Australia
[13] Macquarie Univ, Sydney, NSW, Australia
[14] Univ Colorado, Canc Ctr, Anschutz Med Campus, Aurora, CO USA
[15] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan
[16] Eberhard Karls Univ Tubingen, Tubingen, Germany
[17] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[18] Exelixis Inc, Alameda, CA USA
[19] Bristol Myers Squibb, Princeton, NJ USA
[20] Mem Sloan Kettering Canc Ctr, New York, NY USA
[21] Brigham & Womens Hosp, Lank Ctr Genitourinary Oncol, Dana Farber Canc Inst, Boston, MA USA
[22] Harvard Med Sch, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
603
引用
收藏
页数：1
相关论文
共 50 条
  • [41] JAVELIN renal 101: A randomized, phase III study of avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)
    Motzer, R. J.
    Penkov, K.
    Haanen, J. B. A. G.
    Rini, B. I.
    Albiges, L.
    Campbell, M. T.
    Kollmannsberger, C. K.
    Negrier, S.
    Uemura, M.
    Lee, J. L.
    Gurney, H.
    Berger, R.
    Schmidinger, M.
    Larkin, J.
    Atkins, M. B.
    Wang, J.
    Robbins, P. B.
    Chudnovsky, A.
    Di Pietro, A.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2018, 29 : 724 - 724
  • [42] Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO plus IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.
    Tannir, Nizar M.
    Motzer, Robert J.
    Albiges, Laurence
    Plimack, Elizabeth R.
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Rini, Brian, I
    Grunwald, Viktor
    Hammers, Hans J.
    Choueiri, Toni K.
    Gurney, Howard
    Tykodi, Scott S.
    Porta, Camillo
    Burotto, Mauricio
    Tomita, Yoshihiko
    Lee, Chung-Wei
    Tang, Chad
    McDermott, David F.
    McKay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [43] Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study
    Tomita, Yoshihiko
    Fukasawa, Satoshi
    Shinohara, Nobuo
    Kitamura, Hiroshi
    Oya, Mototsugu
    Eto, Masatoshi
    Tanabe, Kazunari
    Saito, Mitsuru
    Kimura, Go
    Yonese, Junji
    Yao, Masahiro
    Uemura, Hirotsugu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (06) : 506 - 514
  • [44] Efficacy and safety of nivolumab plus ipilimumab (N plus I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.
    Tannir, Nizar M.
    Signoretti, Sabina
    Choueiri, Toni K.
    McDermott, David F.
    Motzer, Robert J.
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Tykodi, Scott S.
    Pal, Sumanta K.
    Gupta, Saurabh
    Lee, Chung-Wei
    McHenry, M. Brent
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [45] Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101)
    Choueiri, Toni K.
    Rini, Brian I.
    Larkin, James M. G.
    Bjarnason, Georg A.
    Gravis, Gwenaelle
    Gurney, Howard
    Lee, Jae-Lyun
    Keizman, Daniel
    Haanen, John B. A. G.
    Tomita, Yoshihiko
    Uemura, Hirotsugu
    Albiges, Laurence
    Schmidinger, Manuela
    Atkins, Michael B.
    Mariani, Mariangela
    Shnaidman, Michael
    Di Pietro, Alessandra
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N plus I) or sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Motzer, Robert J.
    Choueiri, Toni K.
    McDermott, David F.
    Powles, Thomas
    Yao, Jin
    Ammar, Ron
    Papillon-Cavanagh, Simon
    Saggi, Shruti S.
    McHenry, Brent M.
    Ross-Macdonald, Petra
    Wind-Rotolo, Megan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Long-term follow-up on overall survival and independent review of response in CheckMate 214: first-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Grimm, M. -O.
    Tannir, N.
    McDermott, D.
    Escudier, B.
    Hammers, H.
    Aren Frontera, O.
    Plimack, E.
    Barthelemy, P.
    Neiman, V.
    George, S.
    Porta, C.
    Powles, T.
    Donskov, F.
    Amin, A.
    Tykodi, S.
    Tomita, Y.
    Rini, B.
    McHenry, M. B.
    Saggi, S. S.
    Motzer, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 208 - 208
  • [48] Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma
    Liu, Ruizhe
    Qiu, Kaifeng
    Wu, Junyan
    Jiang, Yanqing
    Wu, Peihao
    Pang, Jianxin
    IMMUNOTHERAPY, 2022, 14 (11) : 859 - 869
  • [49] Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Tannir, Nizar M.
    McDermott, David F.
    Escudier, Bernard
    Hammers, Hans J.
    Aren, Osvaldo Rudy
    Plimack, Elizabeth R.
    Barthelemy, Philippe
    Neiman, Victoria
    George, Saby
    Porta, Camillo
    Powles, Thomas
    Donskov, Frede
    Grimm, Marc-Oliver
    Amin, Asim
    Tykodi, Scott S.
    Tomita, Yoshihiko
    Rini, Brian I.
    McHenry, M. Brent
    Saggi, Shruti Shally
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [50] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019)
    Motzer, R. J.
    Rini, B., I
    McDermott, D. F.
    LANCET ONCOLOGY, 2020, 21 (06): : E304 - E304
12345